[68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas

Maria Breun; Camelia M. Monoranu; Camelia M. Monoranu; Almuth F. Kessler; Cordula Matthies; Mario Löhr; Carsten Hagemann; Andreas Schirbel; Steven P. Rowe; Martin G. Pomper; Andreas K. Buck; Hans-Jürgen Wester; Ralf-Ingo Ernestus; Constantin Lapa

doi:10.3389/fonc.2019.00503

Frontiers in Oncology (Jun 2019)

[68Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas

Maria Breun,
Camelia M. Monoranu,
Camelia M. Monoranu,
Almuth F. Kessler,
Cordula Matthies,
Mario Löhr,
Carsten Hagemann,
Andreas Schirbel,
Steven P. Rowe,
Martin G. Pomper,
Andreas K. Buck,
Hans-Jürgen Wester,
Ralf-Ingo Ernestus,
Constantin Lapa

Affiliations

Maria Breun: Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany
Camelia M. Monoranu: Department of Neuropathology, University of Würzburg, Institute of Pathology, Würzburg, Germany
Camelia M. Monoranu: Comprehensive Cancer Center (CCC) Mainfranken, Würzburg, Germany
Almuth F. Kessler: Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany
Cordula Matthies: Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany
Mario Löhr: Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany
Carsten Hagemann: Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany
Andreas Schirbel: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
Steven P. Rowe: Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States
Martin G. Pomper: Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States
Andreas K. Buck: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
Hans-Jürgen Wester: Pharmaceutical Radiochemistry, Technische Universität München, Munich, Germany
Ralf-Ingo Ernestus: Department of Neurosurgery, University Hospital Würzburg, Würzburg, Germany
Constantin Lapa: Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany

DOI: https://doi.org/10.3389/fonc.2019.00503
Journal volume & issue: Vol. 9

Abstract

Read online

We have recently demonstrated CXCR4 overexpression in vestibular schwannomas (VS). This study investigated the feasibility of CXCR4-directed positron emission tomography/computed tomography (PET/CT) imaging of VS using the radiolabeled chemokine ligand [68Ga]Pentixafor.Methods: 4 patients with 6 primarily diagnosed or pre-treated/observed VS were enrolled. All subjects underwent [68Ga]Pentixafor PET/CT prior to surgical resection. Images were analyzed visually and semi-quantitatively for CXCR4 expression including calculation of tumor-to-background ratios (TBR). Immunohistochemistry served as standard of reference in three patients.Results: [68Ga]Pentixafor PET/CT was visually positive in all cases. SUVmean and SUVmax were 3.0 ± 0.3 and 3.8 ± 0.4 and TBRmean and TBRmax were 4.0 ± 1.4 and 5.0 ± 1.7, respectively. Histological analysis confirmed CXCR4 expression in tumors.Conclusion: Non-invasive imaging of CXCR4 expression using [68Ga]Pentixafor PET/CT of VS is feasible and could prove useful for in vivo assessment of CXCR4 expression.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords